Policy & Regulation
First-half reports of supply disruptions for economic reasons hit a record Cancer drugs and vaccines among products dropped; critics call alternative-drug criteria bureaucratic

As pharmaceutical companies successively abandon production of vaccines and essential cancer drugs because of worsening profitability, critics say the Ministry of Food and Drug Safety (MFDS) is effectively leaving most cases unaddressed.
According to Biobook (biobook_d) on the 11th, 47 essential drug supply disruptions were reported for economic reasons in the first half of this year. That was a 56.7% increase from 30 in the first half of 2025.
The figure approaches 82.5% of the 57 supply disruptions reported for economic reasons during all of 2025. The share of all reported supply disruptions attributed to economic reasons also rose 13.2 percentage points from 21.6% in the same period a year earlier, reaching its highest level for a half-year period since 2021.
Most of the products whose production was halted were treatments for serious conditions that are directly tied to patients’ lives. Of the 47 cases reported for economic reasons in the first half of this year, nine (seven ingredients) involved injectable cancer drugs, including dacarbazine, cisplatin, vinblastine, daunorubicin, mitoxantrone, vincristine and fulvestrant.
Other products on the supply-disruption list included fosphenytoin injection, used for emergency treatment of status epilepticus; peritoneal dialysis solution for patients with severe chronic kidney failure; and a cervical cancer vaccine included in the National Immunization Program (NIP).
For 30 of the 47 cases reported for economic reasons, or 63.8%, the MFDS ruled that “no action was needed,” citing the existence of alternative drugs in Korea with the same ingredient or efficacy. Of the remaining cases, 15 were classified as under monitoring or review, while the government directly intervened in just two cases through contract manufacturing.
The administrative approach of considering only whether an alternative drug exists has drawn criticism as bureaucratic. If a particular pharmaceutical company exits the market, demand shifts all at once to the few companies that remain, which are themselves under pressure from rising active pharmaceutical ingredient costs and low reimbursement prices.
There are concerns that treatment shortages and interruptions in medication could occur if the remaining companies also halt production or cannot increase supply. For some cancer drugs, including dacarbazine, manufacturers belatedly announced that they would resume supply or the government approved emergency contract manufacturing support, but these measures came only after appeals from patients and health care providers.
Experts say that because worsening profitability for low-margin essential drugs is a structural problem, the cycle of companies abandoning production could recur without proactive incentives such as advance monitoring, cost reimbursement and more realistic drug prices.
There are also calls for health authorities to carefully assess the actual operating rates of manufacturers with alternative drugs, their ability to secure raw materials and the limits of overall market supply. Without policy improvements such as expanding the list of drugs designated for protection against market withdrawal, adjusting drug prices to reflect rising costs and expanding public contract-manufacturing agreements in advance, the burden of supply disruptions will inevitably fall on patients, critics say.

BIOBOOK TEAM
biobookmedia@biobook.co.kr
The ‘Valley of Death’ for Infectious Disease Treatments: Cross-Agency Coordination Is Key

Mounjaro Costs 59,000 Won in Japan, 300,000 Won in Korea, Sparking Price Debate

SME Ministry aims to develop 20 AI startups valued at 1 trillion won by 2030

MFDS to Commission Domestic Production of 3 Essential Cancer and Antibiotic Drugs, Supply Expected This Year

Up to 6 Bottles of Obesity Drugs Purchased Abroad Allowed Into Korea Starting Tomorrow

‘Public Health Care AI Highway’ Opens, Cutting Referral Form Drafting From 10 Minutes to 1